Oncologist-approved cancer information from the American Society of Clinical Oncology
Printer Friendly
Download PDF

Ewing Family of Tumors - Childhood

This section has been reviewed and approved by the Cancer.Net Editorial Board, 5/2013
Latest Research

ON THIS PAGE: You will read about the scientific research being done now to learn more about this group of tumors and how to treat them. To see other pages in this guide, use the colored boxes on the right side of your screen, or click “Next” at the bottom.

Doctors are working to learn more about EFT, ways to prevent it, how to best treat it, and how to provide the best care to children and teens diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your child’s doctor about the diagnostic and treatment options best for your child.

New chemotherapy. Researchers are evaluating the use of vincristine, cyclophosphamide, and topotecan in addition to standard chemotherapy for patients with newly diagnosed, localized EFT.

Allogeneic stem cell transplantation. In an allogeneic (ALLO) stem cell transplantation (see the Treatment Options section for a description), the child is treated with high doses of chemotherapy and/or radiation therapy to destroy as many tumor cells as possible and to prevent the child's immune system from rejecting the donated stem cells. After the high-dose therapy is given, stem cells obtained from a healthy donor (usually a sibling) are infused into the patient's bloodstream. Allogeneic stem cell transplants combined with sirolimus (Rapamune) and other drugs have been shown to inhibit growth of Ewing cells in the laboratory.

Bilateral lung radiation. The effectiveness of bilateral lung radiation is being examined in patients with metastatic Ewing sarcoma. In this treatment, radiation therapy is given to both lungs after the completion of chemotherapy, and, for some patients, autologous (AUTO) stem cell transplant is recommended.

Insulin-like growth factor receptor-1 (IGF-1R) antibodies. The IGFR is an important growth protein for sarcomas. Inhibiting its activity may be an important new way to improve sarcoma treatment. This new class of treatment is being studied in people with recurrent EFT alone or in combination with other drugs, such as temsirolimus (Torisel).

Supportive care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current EFT treatments, in order to improve patients’ comfort and quality of life.

To find clinical trials specific to your child’s diagnosis, talk with your child’s doctor or search online clinical trial databases now. Please note this link will take you outside this guide.

To continue reading this guide, choose “Next” (below, right) to see a section about coping with the side effects of the disease or its treatment. Or, use the colored boxes located on the right side of your screen to visit any section.

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: